Related Articles
Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan
Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy
Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi‑institute study
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Improved prognosis for elderly patients with metastatic renal cell carcinoma in the era of targeted therapy Corrigendum in /10.3892/mco.2021.2317